Bukowski R, Vaughn C, Bottomley R, Chen T
Cancer Treat Rep. 1982 Feb;66(2):381-3.
The Southwest Oncology Group conducted a phase II study of anguidine in 134 patients with gastrointestinal malignancies. Anguidine was administered as a 4-hour infusion at doses of 3.0 and 4.5 mg/m2 daily x 5. Response rates for patients with colon carcinoma were 22% (four of 18 patients without previous chemotherapy) and 6% (four of 63 patients with previous chemotherapy). There were no responses in patients with pancreatic cancer (four patients) or gastric cancer (six). Toxic effects included thrombocytopenia (19.8%), leukopenia (18.8%), nausea and vomiting (49%), hypotension (37%), and confusion (12%). Antitumor activity of anguidine in patients with colon cancer may be similar to that of 5-FU, but nonhematologic toxicity is substantial.
西南肿瘤协作组对134例胃肠道恶性肿瘤患者进行了安圭定的II期研究。安圭定以每日3.0和4.5mg/m²的剂量进行4小时输注，共5天。结肠癌患者的缓解率分别为22%（18例未接受过化疗的患者中有4例）和6%（63例接受过化疗的患者中有4例）。胰腺癌患者（4例）和胃癌患者（6例）均无缓解。毒性反应包括血小板减少（19.8%）、白细胞减少（18.8%）、恶心和呕吐（49%）、低血压（37%）以及意识障碍（12%）。安圭定对结肠癌患者的抗肿瘤活性可能与5-氟尿嘧啶相似，但非血液学毒性较大。
